Metformin may lower colorectal cancer risk by stopping precancerous lesion formation
the ONA take:
Metformin may lower colorectal cancer risk by reducing the formation of precancerous lesions, according to a study published online ahead of print in the journal Cancer Epidemiology, Biomarkers & Prevention.
Because previous research has suggested that metformin may lower colorectal cancer risk in patients with diabetes and most colorectal cancers originate in precancerous adenomas, researchers from Kaiser Permanente in California and the University of Pennsylvania Perelman School of Medicine sought to determine whether metformin use lowered colorectal adenoma risk following polypectomy in patients with type 2 diabetes.
Researchers retrospectively analyzed data from 2,142 patients age 40 to 89 years with type 2 diabetes, at least one adenoma at baseline colonoscopy, and at least one adenoma at repeat colonoscopy 1 to 10 years from baseline colonoscopy.
Results showed that metformin use was associated with lower adenoma recurrence risk. Researchers found that the association was stronger with increasing total metformin dose.
“Our study suggests a potential benefit of metformin use in lowering the risk of subsequent adenomas after polypectomy in patients with type 2 diabetes,” the authors conclude.
Metformin may lower colorectal cancer risk by reducing the formation of precancerous lesions.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|